BioMarin Pharmaceutical Inc.

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products, Orapred(r) (prednisolone sodium phosphate oral solution) for severe asthma and Aldurazyme(r) (laronidase) for MPS I, and multiple investigational product candidates, including Aryplase(tm) (galsulfase), a Phase 3 product candidate for the treatment of MPS VI and Phenoptin(tm) (sapropterin hydrochloride), a Phase 2 product candidate for the treatment of PKU. For additional information, please visit www.BMRN.com.

Previous Forums
Date/Time		Forum
Dec 7 2004		Bay Area Biotechnology and Healthcare Forum - Foster City CA
Jun 27 2001		BIO 2001 San Diego International Convention - Day 3 of 3
Nov 15 2000		BIO-Europe 2000
Jan 15 2000		BioSpace.com Bay Area Biotechnology Stocks Forum

Market Assistant		PrecisionAlert
Earnings Data Annual Report Press Releases		Enter your email address to receive alerts about this company